Abstract
Lapatinib is an intracellular tyrosine-kinase inhibitor of both EGFR (ErbB1) and HER2 (ErbB2) receptors, which is indicated in the treatment of metastatic disease pretreated with anti-HER2 therapies. We report the clinical case of a woman with chronic renal failure in dialysis affected by HER2-positive metastatic breast neoplasia and treated with lapatinib and letrozole (Oncology).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
